Patents Assigned to Biovitrum AB
-
Publication number: 20100022590Abstract: The present invention relates to novel isoxazole compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of glaucoma.Type: ApplicationFiled: January 15, 2009Publication date: January 28, 2010Applicant: BIOVITRUM AB (publ.)Inventors: Styrbjörn Byström, Martin Haraldsson, Lars Johansson, Jan Tejbrant
-
Patent number: 7618961Abstract: The present invention relates to compounds with the formula (II) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.Type: GrantFiled: May 22, 2001Date of Patent: November 17, 2009Assignee: Biovitrum ABInventors: Tjeerd Barf, Rikard Emond, Guido Kurz, Jerk Vallgårda, Marianne Nilsson
-
Publication number: 20090281087Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: November 12, 2009Applicant: Biovitrum ABInventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom, Viet-Anh Anne Horgan (nee Nguyen), Jaqueline Ouzman, Iain Simpson
-
Patent number: 7582767Abstract: The present invention relates to compounds of the formula (I), wherein R1 and R2 are as defined in the description; to pharmaceutical formulations comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and/or body weight gain.Type: GrantFiled: June 5, 2006Date of Patent: September 1, 2009Assignee: Biovitrum AB (publ.)Inventors: Patrizia Caldirola, Gary Johansson, Lori Sutin
-
Publication number: 20090203695Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: August 13, 2009Applicant: Biovitrum ABInventors: Michael Higginbottom, Viet-Anh Anne Horgan (nee Nguyen), Iain Simpson
-
Patent number: 7572787Abstract: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.Type: GrantFiled: August 25, 2006Date of Patent: August 11, 2009Assignee: Biovitrum ABInventors: Patrizia Caldirola, Ulf Bremberg, Gary Johansson, Andrew Mott, Annika Jenmalm Jensen, Katarina Beierlien, Markus Thor, Lars Tedenborg
-
Patent number: 7566715Abstract: The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.Type: GrantFiled: August 30, 2005Date of Patent: July 28, 2009Assignee: Biovitrum ABInventors: Ulf Bremberg, Patrizia Caldirola, Annika J. Jensen, Gary Johansson, Lori Sutin, Andrew Mott, Jan Tejbrant
-
Publication number: 20090181967Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: July 16, 2009Applicant: Biovitrum ABInventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom
-
Publication number: 20090176798Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: July 9, 2009Applicant: Biovitrum ABInventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom
-
Patent number: 7534794Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are asType: GrantFiled: October 11, 2002Date of Patent: May 19, 2009Assignee: Biovitrum ABInventors: Björn Nilsson, Jan Tejbrant, Benjamin Pelcman, Erik Ringberg, Markus Thor, Jonas Nilsson, Mattias Jönsson
-
Publication number: 20080293694Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: ApplicationFiled: March 13, 2008Publication date: November 27, 2008Applicant: Biovitrum AB (publ.)Inventors: Johan Angbrant, Peter Brandt, Rune Ringom, Bengt Lindqvist
-
Publication number: 20080255153Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.Type: ApplicationFiled: March 27, 2008Publication date: October 16, 2008Applicant: BIOVITRUM AB (publ)Inventors: Ulf Bremberg, Auri Linden, Thomas Lundback, Jonas Nilsson, Marie Wiik, Magnus Bergner, Peter Brandt, Kristin Hammer, Rune Ringom
-
Publication number: 20080076776Abstract: Compounds of formula (I) below are disclosed. Their use as medicaments is described, in particular for the treatment of pain or inflammation: wherein: when X?Y=Z=OH, R1 is OCH2CF2CF3, phenoxy (substituted with 3-(4-trifluoromethylphenyl), 3,4-dichloro, (3-trifluoromethyl,4-fluoro), (3-trifluoromethyl,4-chloro), (3-chloro, 4-cyano), or 3,5-bis(trifluoromethyl)), 1-piperazinyl(4-(3,4-dichlorophenyl)), phenyl (substituted with 3,4-dichloro, 3,5-difluoro, 3,5-bis(trifluoromethyl) or 3,4,5-trifluoro) or 2-benzofuranyl; or when X?Y?OH and Z=OMe, R1 is OCH3, OCH2CHF2, OCH2cyclopentyl, O-(2,5-difluorophenyl) or (S)-sec-butylamino; or when X?H and Y=Z=OH, R1 is n-hexylamino or cyclopentylamino; or when (IV) X=Z=OH and Y?H, R1 is cyclopentylamino; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 26, 2007Publication date: March 27, 2008Applicant: BIOVITRUM ABInventors: Michael Higginbottom, Edward Savory, Giles Brown, Viet-Anh Horgan, Emma Chapman
-
Patent number: 7319097Abstract: The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous systemType: GrantFiled: August 30, 2005Date of Patent: January 15, 2008Assignee: Biovitrum ABInventors: Ulf Bremberg, Patrizia Caldirola, Annika J. Jensen, Gary Johansson, Lori Sutin, Andrew Mott, Jan Tejbrant
-
Publication number: 20080009461Abstract: The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2?-methoxy adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds, in particular as analgesic or anti-inflammatory compounds, or as disease modifying antirheumatic drugs (DMARDs), and to methods of preventing, treating or ameliorating pain or inflammation using these compounds.Type: ApplicationFiled: June 26, 2007Publication date: January 10, 2008Applicant: BIOVITRUM ABInventor: Edward Savory
-
Patent number: 7285392Abstract: The present invention relates to methods for identifying agents that modulate the effect of cytokine class I receptor binding compounds, by inhibiting the interaction between the cytokine class I receptor and nuclear factors. The agents are useful for decreasing IGF-1 levels in a cell, and for the treatment of medical disorders caused by hormone dysregulation, such as growth hormone or prolactin dysregulation.Type: GrantFiled: June 28, 2004Date of Patent: October 23, 2007Assignee: Biovitrum ABInventors: Vendela Parrow, Lotta Moréus
-
Patent number: 7253196Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.Type: GrantFiled: May 24, 2005Date of Patent: August 7, 2007Assignees: Amgen, Inc., Biovitrum ABInventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
-
Patent number: 7247633Abstract: A compound of the general formula (I): wherein R1, R2, X, Y and Z are as described in the specification.Type: GrantFiled: July 14, 2003Date of Patent: July 24, 2007Assignee: Biovitrum ABInventor: Björn M. Nilsson
-
Patent number: 7244722Abstract: Compounds of the general formula (I): wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.Type: GrantFiled: July 17, 2003Date of Patent: July 17, 2007Assignee: Biovitrum ABInventors: Magnus Cernerud, Helena Lundström, Björn M Nilsson, Markus Thor
-
Patent number: 7229997Abstract: Compounds of the general formula (I): wherein R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament which particularly acts on the central nervous system, particularly for use as anti-obesity agents.Type: GrantFiled: May 16, 2003Date of Patent: June 12, 2007Assignee: Biovitrum ABInventors: Björn M. Nilsson, Erik Ringberg